Compare TG Therapeutics Inc (TGTX) vs Tesla, Inc. (TSLA) Price & Performance

TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.

The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.

Tesla (TSLA) trades at $368.16, up 3.98% in the last 24 hours, with a bullish technical signal from moving averages and ADX indicators. Recent earnings show a mix of beats and a miss, with Q2 2026 EPS of $0.33 falling short of the $0.50 estimate. The company's revenue declined to $94.83 billion in 2025, and net income margin compressed to 3.67%, while valuation ratios like P/E of 340.89 remain elevated. Positive news includes regulatory approval for self-driving software in Europe and a surge in German registrations.

Tesla's outlook hinges on execution in autonomous driving and energy segments, but high valuation and margin pressures pose risks. Analyst consensus is mixed with a $398.38 price target, suggesting moderate upside, though competition and demand volatility require caution for investors.